Blar i forfatter "Sørlie, Therese"

Viser treff 1-6 av 6

    • Differential in vivo tumorigenicity of distinct subpopulations from a luminal-like breast cancer xenograft 

      Skrbo, Nirma; Hjortland, Geir Olav; Kristian, Alexandr; Holm, Ruth; Nordgard, Silje H.; Prasmickaite, Lina; Engebråten, Olav; Mælandsmo, Gunhild; Sørlie, Therese; Andersen, Kristin (Journal article; Tidsskriftartikkel; Peer reviewed, 2014)

    • The expression of the long NEAT1_2 isoform is associated with human epidermal growth factor receptor 2-positive breast cancers 

      Knutsen, Erik; Lellahi, Seyed Mohammad; Aure, Miriam Ragle; Nord, Silje; Fismen, Silje; Larsen, Kenneth Bowitz; Tellez Gabriel, Marta; Hedberg, Annica; Bjørklund, Sunniva; Bofin, Anna M.; Mælandsmo, Gunhild Mari; Sørlie, Therese; Mortensen, Elin Synnøve; Perander, Maria (Journal article; Tidsskriftartikkel; Peer reviewed, 2020-01-28)
      The long non-coding RNA <i>NEAT1</i> locus is transcribed into two overlapping isoforms, <i>NEAT1_1</i> and <i>NEAT1_2</i>, of which the latter is essential for the assembly of nuclear paraspeckles. <i>NEAT1</i> is abnormally expressed in a wide variety of human cancers. Emerging evidence suggests that the two isoforms have distinct functions in gene expression regulation, and recently it was shown ...

    • Interplay of choline metabolites and genes in patient-derived breast cancer xenografts 

      Grinde, Maria Tunset; Skrbo, Nirma; Moestue, Siver Andreas; Rødland, Einar Andreas; Borgan, Eldrid; Kristian, Alexandr; Sitter, Beathe; Bathen, Tone; Børresen-Dale, Anne-Lise; Mælandsmo, Gunhild; Sørlie, Therese; Marangoni, Elisabetta; Gribbestad, Ingrid S (Journal article; Tidsskriftartikkel; Peer reviewed, 2014-01-21)
      Introduction: Dysregulated choline metabolism is a well-known feature of breast cancer, but the underlying mechanisms are not fully understood. In this study, the metabolomic and transcriptomic characteristics of a large panel of human breast cancer xenograft models were mapped, with focus on choline metabolism. <br> Methods: Tumor specimens from 34 patient-derived xenograft models were collected ...

    • LIMT is a novel metastasis inhibiting lncRNA suppressed by EGF and downregulated in aggressive breast cancer 

      Sas-Chen, Aldema; Aure, Miriam Ragle; Leibovich, Limor; Carvalho, Silvia; Enuka, Yehoshua; Körner, Cindy; Polycarpou-Schwarz, Maria; Lavi, Sara; Nevo, Nava; Kuznetsov, Yuri; Yuan, Justin; Azuaje, Francisco; Ulitsky, Igor; Diederichs, Sven; Wiemann, Stefan; Yakhini, Zohar; Kristensen, Vessela N.; Børresen-Dale, Anne-Lise; Yarden, Yosef; Sauer, Torill; Geisler, Jürgen; Hofvind, Solveig; Bathen, Tone Frost; Borgen, Elin; Engebråten, Olav; Fodstad, Øystein; Garred, Øystein; Geitvik, Gry; Kåresen, Rolf; Naume, Bjørn; Mælandsmo, Gunhild; Russnes, Hege Elisabeth Giercksky; Schlichting, Ellen; Sørlie, Therese; Lingjærde, Ole Christian; Sahlberg, Kristine Kleivi; Skjerven, Helle; Fritzman, Britt (Journal article; Tidsskriftartikkel; Peer reviewed, 2016-09-01)
      Long noncoding RNAs (lncRNAs) are emerging as regulators of gene expression in pathogenesis, including cancer. Recently, lncRNAs have been implicated in progression of specific subtypes of breast cancer. One aggressive, basal-like subtype associates with increased EGFR signaling, while another, the HER2-enriched subtype, engages a kin of EGFR Based on the premise that EGFR-regulated lncRNAs might ...

    • Liver X receptors induce antiproliferative effects in basal-like breast cancer 

      Haugen, Mads; von der Lippe Gythfeldt, Hedda; Egeland, Eivind Valen; Svartdal Normann, Lisa; Pandya, Abhilash D.; Vedin, Lise-Lotte; Juell, Siri; Tenstad, Ellen; Øy, Geir Frode; Kristian, Alexandr; Marangoni, Elisabetta; Sørlie, Therese; Steffensen, Knut Rune; Mælandsmo, Gunhild Mari; Engebråten, Olav (Journal article; Tidsskriftartikkel; Peer reviewed, 2023-06-21)
      Liver X receptors (LXRs) are nuclear transcription factors important in the regulation of cholesterol transport, and glucose and fatty acid metabolism. The antiproliferative role of LXRs has been studied in a variety of malignancies and may represent a therapeutic opportunity in cancers lacking targeted therapies, such as triple-negative breast cancer. In this study, we investigated the impact of ...

    • Subtype-specific response to bevacizumab is reflected in the metabolome and transcriptome of breast cancer xenografts 

      Borgan, Eldrid; Lindholm, Evita Maria; Moestue, Siver Andreas; Mælandsmo, Gunhild; Lingjærde, Ole Christian; Gribbestad, Ingrid S; Børresen-Dale, Anne-Lise; Engebråten, Olav; Sørlie, Therese (Journal article; Tidsskriftartikkel; Peer reviewed, 2012-10-23)
      <p>Antiangiogenic therapy with bevacizumab has shown varying results in breast cancer clinical trials. Identifying robust biomarkers for selecting patients who may benefit from such treatment and for monitoring response is important for the future use of bevacizumab.</p> <p>Two established xenograft models representing basal‐like and luminal‐like breast cancer were used to study bevacizumab ...